Table 1 (abstract P159). Treatment of patients with monogenic AIDs with hematological symptoms
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Therapy | Patient (n) | Hematological response | Â | Â |
|---|---|---|---|---|
full | partial | no effect | ||
Jak-inhibitors | 11 | 5 | 2 | 4 |
Anti-TNFα | 5 | 0 | 2 | 3 |
Anti-IL1/ Anti-IL6 | 11/4 | 4/0 | 2/0 | 5/4 |
Jak-inhibitors+Anti-TNFα | 3 | 1 | 1 | 1 |
Jak-inhibitors+Anti-IL6 | 3 | 0 | 1 | 2 |
Anti-IL6+ Sirolimus | 2 | 0 | 1 | 1 |
Jak-inhibitors+rituximab+ Anti-IL6 | 3 | 0 | 2 | 1 |
Jak-inhibitors+rituximab+ Steroides | 4 | 1 | 3 | 0 |